Skip to main content

CeMines Estonian Subsidiary Receives CE Mark for Lung Cancer Dx

NEW YORK, Jan. 12 (GenomeWeb News) - The European Union's regulatory body cleared the CellCorrect Lab Detection Kit for clinical use, CeMines said today.


EU's State Agency of Medicines-Department of Medical Devices on Dec. 30, 2005, granted the CE Mark for the molecular blood test to detect and diagnose lung cancer. CeMines Estonia OU, a wholly owned subsidiary, filed for CE Mark registration in September 2005.  


CeMines Estonia will market and distribute the test under the brand name CellCorrect KvA-40 LAb Kit.


CeMines filed a 501(k) application for CellCorrect Lab with the US Food and Drug Administration in May 2005. Claiming "productive discussions" with the FDA, the company expects "substantial forward progress" in 2006.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.